Adequan 100 mg/ml solution for injection

Country: Ireland

Language: English

Source: HPRA (Health Products Regulatory Authority)

Buy It Now

Active ingredient:

polysulphated glycosaminoglycan

Available from:

Novartis Animal Health UK Ltd

ATC code:

QM01AX12

Dosage:

100 Mg/Ml

Pharmaceutical form:

Solution for Injection

Therapeutic group:

Equine - Food

Therapeutic area:

N.S.A.I.D

Authorization status:

Authorised

Summary of Product characteristics

                                SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE VETERINARY MEDICINAL PRODUCT
Adequan 100 mg/ml Solution for Injection
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
Active Substance:
Polysulphated Glycosaminoglycan (PSGAG) 100 mg/ml
For a full list of excipients see section 6.1.
3 PHARMACEUTICAL FORM
Solution for injection.
Clear, colourless to pale yellow aqueous solution.
4 CLINICAL PARTICULARS
4.1 TARGET SPECIES
Horse.
4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
For treatment of lameness in horses due to traumatic or degenerative aseptic joint disease and acute superficial digital
flexor tendonitis.
4.3 CONTRAINDICATIONS
Do not use in animals with known hypersensitivity to the active ingredient.
Do not use in cases of advanced renal or hepatic disease.
Do not use in pregnant animals.
4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES
None.
IRISH MEDICINES BOARD
________________________________________________________________________________________________________________________
_Date Printed 22/10/2010_
_CRN 7007731_
_page number: 1_
4.5 SPECIAL PRECAUTIONS FOR USE
SPECIAL PRECAUTIONS FOR USE IN ANIMALS
For intramuscular administration only
If signs or symptoms of hypersensitivity occur, the treatment must be discontinued
SPECIAL PRECAUTIONS TO BE TAKEN BY THE PERSON ADMINISTERING THE VETERINARY MEDICINAL PRODUCT TO ANIMALS
Care should be taken to avoid accidental self-injection.
In the case of accidental eye or skin contact, wash the affected area thoroughly with copious amounts of water. If
irritation persists, seek medical attention.
4.6 ADVERSE REACTIONS (FREQUENCY AND SERIOUSNESS)
None known
4.7 USE DURING PREGNANCY, LACTATION OR LAY
Adequan should not be used in pregnant animals.
4.8 INTERACTION WITH OTHER MEDICINAL PRODUCTS AND OTHER FORMS OF INTERACTION
Adequan may potentiate the action of anticoa
                                
                                Read the complete document